JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on August 29, 2006; DOI: 10.1124/jpet.106.108878


0022-3565/06/3192-663-671$20.00
JPET 319:663-671, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
jpet.106.108878v1
319/2/663    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pyriochou, A.
Right arrow Articles by Papapetropoulos, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pyriochou, A.
Right arrow Articles by Papapetropoulos, A.

CARDIOVASCULAR

Soluble Guanylyl Cyclase Activation Promotes AngiogenesisFormula

Anastasia Pyriochou, Dimitris Beis, Vasiliki Koika, Christos Potytarchou, Evangelia Papadimitriou, Zongmin Zhou, and Andreas Papapetropoulos

Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, Greece (A.P., V.K., C.P., E.P., A.P.); Foundation for Biomedical Research of the Academy of Athens, Basic Research Center, Cell Biology, Athens, Greece (D.B.); and "G.P. Livanos and M. Simou" Laboratories, Evangelismos Hospital, Department of Critical Care and Pulmonary Services, University of Athens School of Medicine, Athens, Greece (Z.Z.)

Soluble guanylyl cyclase (sGC) is a cGMP-generating enzyme carrying a heme prosthetic group that functions as a nitric oxide (NO) sensor. sGC is present in most cells types, including the vascular endothelium, where its biological functions remain largely unexplored. Herein, we have investigated the role of sGC in angiogenesis and angiogenesis-related properties of endothelial cells (EC). Initially, we determined that sGC was present and enzymatically active in the chicken chorioallantoic membrane (CAM) during the days of maximal angiogenesis. In the CAM, inhibition of endogenous sGC inhibited neovascularization, whereas activation promoted neovessel formation. Using zebrafish as a model for vascular development, we did not detect any effect on vasculogenesis upon sGC blockade, but we did observe an abnormal angiogenic response involving the cranial and intersegmental vessels, as well as the posterior cardinal vein. In vitro, pharmacological activation of sGC or adenovirus-mediated sGC gene transfer promoted EC proliferation and migration, whereas sGC inhibition blocked tube-like network formation. In addition, sGC inhibition blocked the migratory response to vascular EC growth factor. Cells infected with sGC-expressing adenoviruses exhibited increased extracellular signal-regulated kinase 1/2 and p38 MAPK activation that was sensitive to sGC inhibition by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, suggesting that these mitogen-activated protein kinases are downstream effectors of sGC in EC. A functional role for p38 in cGMP-stimulated migration was demonstrated using SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole]; pharmacological inhibition of p38 attenuated BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-4-ylamine] and sGC overexpression-induced EC mobilization. We conclude that sGC activation promotes the expression of angiogenesis-related properties by EC and that sGC might represent a novel target to modulate neovessel formation.


Received June 2, 2006; accepted August 28, 2006.

Address correspondence to: Dr. Andreas Papapetropoulos, Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras 26504, Greece. E-mail: apapapet{at}upatras.gr




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Z. Zhou, A. Pyriochou, A. Kotanidou, G. Dalkas, M. van Eickels, G. Spyroulias, C. Roussos, and A. Papapetropoulos
Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress
Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1763 - H1771.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
K. Kajiya, R. Huggenberger, I. Drinnenberg, B. Ma, and M. Detmar
Nitric oxide mediates lymphatic vessel activation via soluble guanylate cyclase {alpha}1{beta}1-impact on inflammation
FASEB J, February 1, 2008; 22(2): 530 - 537.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
A. Schmidt, K. Brixius, and W. Bloch
Endothelial Precursor Cell Migration During Vasculogenesis
Circ. Res., July 20, 2007; 101(2): 125 - 136.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.